Monoclonal Antibodies as a Site Specific Particulate Drug Delivery System: A Review
-
Published:2022-11-23
Issue:
Volume:
Page:286-292
-
ISSN:2231-5675
-
Container-title:Asian Journal of Pharmaceutical Analysis
-
language:en
-
Short-container-title:AJPA
Author:
Shinde. G.S.1, Prasad Kumbhar1, Jadhav. R.S.2, Vikhe. D. N2
Affiliation:
1. Department of Pharmaceutical Chemistry, Pravara Rural College of Pharmacy, Pravaranagar. Tal - Rahata, Dist.- Ahmednagar. 2. Department of Pharmacognosy, Pravara Rural College of Pharmacy, Pravaranagar. Tal - Rahata, Dist.- Ahmednagar.
Abstract
Monoclonal antibodies are antibodies that are identical because they were produced by one type of immune cell, all Human monoclonal antibody immunotherapy in clinical medicine has been an exciting prospect for some time, and increasing numbers of such antibodies have gradually become available. Targets and basic characterization of novel classes of bioactive agents, to the development of ‘designer’ or ‘smart’ materials which provide required excipient or carrier properties to achieve modulated and targeted drug delivery. Drug particle engineering, or crystal engineering, provides an additional dimension to drug delivery and targeting. Traditional methods of particle formation, crystallization. Antibodies can be heterogeneous with respect to size, charge, antigen specificity, and affinity. These factors may be significant when antibodies are used as a drug delivery system. Drug targeting and delivery using antibodies has been most useful in the field of chemotherapy because this is an area of research in which there is the greatest need for target-site specificity. Antibodies have been found to have many applications in the management of human carcinomas, including colorectal, gastric, ovarian, endometrial, breast, lung.
Publisher
A and V Publications
Reference44 articles.
1. Larson, S.M., Brown, J.P., Wright, P.W., Carrasquillo, J.A., Hellstrom, I., andhellstrom, K.E., Imaging of melanoma with I-labeled monoclonal antibodies, J. Nuclear Med. 24, 123–129, 1983. 2. Zurawski, V.R., Haber, E., and Black, P.H., Production of antibody to tetanus Toxoid by continuous human lymphoblastoid cell lines, Science, 199, 1439,1978. 3. Trout, A., Increased selectivity of drugs by linking to carriers, Eur. J. Cancer,14, 105, 1978. 4. Steinitz, M., Klein, G., Koskimies, S., and Makela, O., EB virus-induced B-lymphocyte Cell lines producing specific antibody, Nature, 269, 420, 1977. 5. Birch, J.R., Cells sell, Chemtech, 17(6), 378–381, 1987.
|
|